Items Tagged ‘cabozantinib’

December 5th, 2016

Cabometyx™ Improves Time to Cancer Progression as Initial Therapy in Kidney Cancer

By

The agent Cabometyx™ (cabozantinib) improves anti-cancer responses and time to cancer progression compared to Sutent® (sunitinib) when used as initial therapy for advanced kidney cancer. These results were recently published in the Journal of Clinical Oncology. The kidneys are a pair of organs with multiple functions. Renal cell carcinoma is the most common type of […]

View full entry

Tags: AXL, Cabometyx, cabozantinib, General Renal Cancer, kidney cancer, MET, metastatic, mRCC, News, Renal Cancer, sunitinib, Sutent


July 26th, 2016

Cabozantinib Does Not Demonstrate Improvements in Advanced Prostate Cancer

By

In a recent study, the targeted agent cabozantinib did not demonstrate an improvement in outcomes compared to prednisone, among men with advanced prostate cancer. These results were recently published in the Journal of Clinical Oncology. Prostate cancer is the second leading cause of cancer-related deaths among men in the United States.  Metastatic prostate cancer refers […]

View full entry

Tags: cabozantinib, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer


May 10th, 2016

Cabometyx® Approved for Kidney Cancer

By

The United States Food and Drug Administration (FDA) has approved the kinase inhibitor Cabometyx (cabozantinib) for the treatment of renal cell carcinoma (kidney cancer). The approval is for patients with advanced renal cell carcinoma who have already been treated with prior anti-angiogenic therapy. Each year in the United States, more than 61,000 people are diagnosed […]

View full entry

Tags: Cabometyx, cabozantinib, General Renal Cancer, kidney cancer, kinase inhibitor, metastatic, News, rcc, Renal Cancer, renal cell carcinoma


October 15th, 2015

COMETRIQ® Improves Progression-Free Survival in Kidney Cancer

By

According to a recently published study in the New England Journal of Medicine, the targeted agent, COMETRIQ® (cabozantinib), significantly improves the time to cancer progression and survival compared to Afinitor® (everolimus) in patients with advanced kidney cancer whose cancer has progressed following VEGRF-targeted therapy. Each year in the United States, more than 58,000 people are […]

View full entry

Tags: afinitor, cabozantinib, COMETRIQ, General Renal Cancer, kidney cancer, News, rcc, Renal Cancer, VEGFR-targeted agents


September 3rd, 2014

Cabozantinib Development in Prostate Cancer Halted

By

Development of the investigational drug cabozantinib that initially showed promise in the treatment of metastatic, hormone-refractory prostate cancer has been halted due to discouraging results in a pivotal clinical trial.  Enrollment in a second, phase III study of cabozantinib in prostate cancer has also been halted based on the negative outcome from the first study. Prostate […]

View full entry

Tags: cabozantinib, hormone refractory, Metastatic Stage IV (D) Prostate Cancer, News, Prostate Cancer, Refactory/Recurrent Prostate Cancer